Francisco Dasí. (2023) Alpha-1 antitrypsin deficiency. Medicina Clínica.
Crossref
Theodore S. Kapellos, Thomas M. Conlon, Ali Önder Yildirim & Mareike Lehmann. (2023) The impact of the immune system on lung injury and regeneration in COPD. European Respiratory Journal 62:4, pages 2300589.
Crossref
Leonard Riley, Aryaman Sriram, Mark Brantly & Jorge Lascano. (2023) Testing Patterns and Disparities for Alpha-1 Antitrypsin Deficiency. The American Journal of Medicine 136:10, pages 1011-1017.
Crossref
Daniella A. Spittle, Alison Mansfield, Anita Pye, Alice M. Turner & Michael Newnham. (2023) Predicting Lung Function Using Biomarkers in Alpha-1 Antitrypsin Deficiency. Biomedicines 11:7, pages 2001.
Crossref
N. A. Karchevskaya, M. S. Kevorkova, E. А. Tarabrin, T. Е. Kallagov, I. U. Ibavov, E. I. Pervakova, A. L. Cherniaev, M. V. Samsonova, M. Sh. Khubutiya & A. G. Chuchalin. (2022) Lung transplantation in a patient with α<sub>1</sub>-antitrypsin deficiency emphysema. PULMONOLOGIYA 32:6, pages 899-905.
Crossref
J.-F. Mornex, M. Balduyck, M. Bouchecareilh, A. Cuvelier, R. Epaud, M. Kerjouan, O. Le Rouzic, C. Pison, L. Plantier, M.-C. Pujazon, M. Reynaud-Gaubert, A. Toutain, B. Trumbic, M.-C. Willemin, M. Zysman, O. Brun, M. Campana, F. Chabot, V. Chamouard, M. Dechomet, J. Fauve, B. Girerd, C. Gnakamene, S. Lefrançois, J.-N. Lombard, B. Maitre, C. Maynié-François, A. Moerman, A. Payancé, P. Reix, D. Revel, M.-P. Revel, M. Schuers, P. Terrioux, D. Theron, F. Willersinn, V. Cottin & H. Mal. (2022) Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge. Revue des Maladies Respiratoires 39:7, pages 633-656.
Crossref
Bruno BALBI, Federica BENINI, Luciano CORDA, Angelo CORSICO, Ilaria FERRAROTTI & Nuccia GATTA. (2022) An Italian expert consensus on the management of alpha1-antitrypsin deficiency: a comprehensive set of algorithms. Panminerva Medica 64:2.
Crossref
G. Guarnieri, A. Achille, S. Lococo & A. Vianello. (2022) Pregnancy in Alpha 1 Antitrypsin (AAT) Deficiency and the role of intravenous AAT therapy. Pulmonology 28:4, pages 317-319.
Crossref
Annalisa Bianchera, Esraa Alomari & Stefano Bruno. (2022) Augmentation Therapy with Alpha-1 Antitrypsin: Present and Future
of Production, Formulation, and Delivery. Current Medicinal Chemistry 29:3, pages 385-410.
Crossref
Kenneth R. Chapman. (2022) If All That You Have Is a Hammer…: Can We Phenotype Our Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine 205:3, pages 266-267.
Crossref
Robert Andrew Stockley. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine
675
685
.
Caroline A. Owen. 2022. Encyclopedia of Respiratory Medicine. Encyclopedia of Respiratory Medicine
541
557
.
Timm Greulich & Martina Veith. 2022. Seltene Lungenerkrankungen. Seltene Lungenerkrankungen
495
512
.
Iris G.M. Schouten, Marise J. Kasteleyn, Roula Tsonaka, Robert Bals, Alice C. Turner, Ilaria Ferrarotti, Angelo G. Corsico, Beatriz Lara, Marc Miravitlles, Robert A. Stockley & Jan Stolk. (2021)
Long-term effect of α
1
-antitrypsin augmentation therapy on the decline of FEV
1
in deficient patients: an analysis of the AIR database
. ERJ Open Research 7:3, pages 00194-2021.
Crossref
Anna Annunziata, Maurizia Lanza, Antonietta Coppola, Paolo Andreozzi, Sara Spinelli & Giuseppe Fiorentino. (2021) Alpha-1 Antitrypsin Deficiency: Home Therapy. Frontiers in Pharmacology 12.
Crossref
Simona Viglio, Elisabeth G. Bak, Iris G. M. Schouten, Paolo Iadarola & Jan Stolk. (2021) Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches. International Journal of Molecular Sciences 22:3, pages 1065.
Crossref
Igor Barjaktarevic & Michael Campos. (2021) Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Therapeutic Advances in Chronic Disease 12_suppl, pages 204062232110101.
Crossref
Jan Sieluk, Julia F. Slejko, Henry Silverman, Eleanor Perfetto & C. Daniel Mullins. (2020) Medical costs of Alpha-1 antitrypsin deficiency-associated COPD in the United States. Orphanet Journal of Rare Diseases 15:1.
Crossref
Mark Brantly, Michael Campos, Angela M. Davis, Jeanine D’Armiento, Kenneth Goodman, Kathi Hanna, Miriam O’Day, John Queenan, Robert Sandhaus, James Stoller, Charlie Strange, Jeffrey Teckman & Adam Wanner. (2020) Detection of alpha-1 antitrypsin deficiency: the past, present and future. Orphanet Journal of Rare Diseases 15:1.
Crossref
Fernanda Martini, Monica De Mattei, Carlo Contini & Mauro G. Tognon. (2020) Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment. Frontiers in Cell and Developmental Biology 8.
Crossref
Kenneth R. Chapman. (2020) Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology 63:4, pages 403-404.
Crossref
Simona Viglio, Paolo Iadarola, Maura D’Amato & Jan Stolk. (2020) Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History. Molecules 25:17, pages 4014.
Crossref
Roxana Cortes-Lopez & Igor Barjaktarevic. (2020) Alpha-1 Antitrypsin Deficiency: a Rare Disease?. Current Allergy and Asthma Reports 20:9.
Crossref
Ahmad Karadagi, Alex G. Cavedon, Helen Zemack, Greg Nowak, Marianne E. Eybye, Xuling Zhu, Eleonora Guadagnin, Rebecca A. White, Lisa M. Rice, Andrea L. Frassetto, Stephen Strom, Carl Jorns, Paolo G. V. Martini & Ewa Ellis. (2020) Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency. Scientific Reports 10:1.
Crossref
Mario Cazzola, Daiana Stolz, Paola Rogliani & Maria Gabriella Matera. (2020)
α
1
-Antitrypsin deficiency and chronic respiratory disorders
. European Respiratory Review 29:155, pages 190073.
Crossref
Jack Dummer, Claudia C. Dobler, Mark Holmes, Daniel Chambers, Ian A. Yang, Lianne Parkin, Sheree Smith, Peter Wark, Anouk Dev, Sandra Hodge, Eli Dabscheck, Julian Gooi, Sameh Samuel, Steven Knowles & Anne E. Holland. (2020) Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology 25:3, pages 321-335.
Crossref
R. Zapater López, N. Marcos Carrasco, L. Téllez Villajos & J. Martínez González. (2020) Enfermedades hepáticas de causa metabólica. Medicine - Programa de Formación Médica Continuada Acreditado 13:4, pages 191-202.
Crossref
Stephan F. van Eeden & James C. Hogg. (2020) Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. Respiration 99:7, pages 550-565.
Crossref
Nestor A. Molfino. 2020. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics
361
403
.
Franck Rahaghi, Laurel Omert, Virginia Clark & Robert A. Sandhaus. (2019) Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD. Journal of Critical Care 54, pages 212-219.
Crossref
Sabina Janciauskiene & Tobias Welte. 2019.
α
1
-Antitrypsin Deficiency
.
α
1
-Antitrypsin Deficiency
159
178
.
Michael A. Campos, Patrick Geraghty, Gregory Holt, Eliana Mendes, Paul R. Newby, Shuren Ma, Landy V. Luna-Diaz, Gerard M. Turino & Robert A. Stockley. (2019) The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial. American Journal of Respiratory and Critical Care Medicine 200:3, pages 318-326.
Crossref
Hannah A. Blair. (2019) Human α1-proteinase inhibitor (Respreeza®) in α1-antitrypsin deficiency emphysema: a profile of its use in the EU. Drugs & Therapy Perspectives 35:8, pages 363-368.
Crossref
Paul R. Newby, Diana Crossley, Helena Crisford, James A. Stockley, Richard A. Mumford, Richard I. Carter, Charlotte E. Bolton, Nicholas S. Hopkinson, Ravi Mahadeva, Michael C. Steiner, Tom M.A. Wilkinson, Elizabeth Sapey & Robert A. Stockley. (2019)
A specific proteinase 3 activity footprint in α
1
-antitrypsin deficiency
. ERJ Open Research 5:3, pages 00095-2019.
Crossref
Marinos Pericleous, Claire Kelly, Aftab Ala & Michael L. Schilsky. 2019. Clinical Epidemiology of Chronic Liver Diseases. Clinical Epidemiology of Chronic Liver Diseases
307
330
.
María Torres-Durán, José Luis Lopez-Campos, Miriam Barrecheguren, Marc Miravitlles, Beatriz Martinez-Delgado, Silvia Castillo, Amparo Escribano, Adolfo Baloira, María Mercedes Navarro-Garcia, Daniel Pellicer, Lucía Bañuls, María Magallón, Francisco Casas & Francisco Dasí. (2018) Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet Journal of Rare Diseases 13:1.
Crossref
A.P. Lopes, M.A. Mineiro, F. Costa, J. Gomes, C. Santos, C. Antunes, D. Maia, R. Melo, M. Canotilho, E. Magalhães, I. Vicente, C. Valente, B.G. Gonçalves, B. Conde, C. Guimarães, C. Sousa, J. Amado, M.E. Brandão, M. Sucena, M.J. Oliveira, S. Seixas, V. Teixeira & L. Telo. (2018) Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 24, pages 1-21.
Crossref
Timothy J. Craig & Maria Paula Henao. (2018)
Advances in managing COPD related to α
1
-antitrypsin deficiency: An under-recognized genetic disorder
. Allergy 73:11, pages 2110-2121.
Crossref
Minsun Kim, Qing Cai & Youngman Oh. (2018) Therapeutic potential of alpha-1 antitrypsin in human disease. Annals of Pediatric Endocrinology & Metabolism 23:3, pages 131-135.
Crossref
Article Editorial. (2018) Diagnosis and treatment of pulmonarydisease in α1-antitrypsin deficiency: a statement of European Respiratory Society. Russian Pulmonology 28:3, pages 273-295.
Crossref
Sebastian Fähndrich, Nikolas Bernhard, Philipp Lepper & Robert Bals. (2018) Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie. Pneumo News 10:2, pages 31-40.
Crossref
Michael A. Campos, Michael C. Runken, Angela M. Davis, Michael P. Johnson, Glenda A. Stone & Ami R. Buikema. (2018) Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis. Advances in Therapy 35:4, pages 467-481.
Crossref
Gabriel Thabut & Luciano Corda. (2018) Epidemiology, Diagnosis and Available Treatment for Alpha 1 Antitrypsin Deficiency-related Emphysema in Europe. European Respiratory & Pulmonary Diseases 4:1, pages 25.
Crossref
Franck F. Rahaghi & Marc Miravitlles. (2017) Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respiratory Research 18:1.
Crossref
Marc Miravitlles, Asger Dirksen, Ilaria Ferrarotti, Vladimir Koblizek, Peter Lange, Ravi Mahadeva, Noel G. McElvaney, David Parr, Eeva Piitulainen, Nicolas Roche, Jan Stolk, Gabriel Thabut, Alice Turner, Claus Vogelmeier & Robert A. Stockley. (2017)
European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α
1
-antitrypsin deficiency
. European Respiratory Journal 50:5, pages 1700610.
Crossref
Michael A. Tortorici, James A. Rogers, Oliver Vit, Martin Bexon, Robert A. Sandhaus, Jonathan Burdon, Joanna Chorostowska-Wynimko, Philip Thompson, James Stocks, Noel G. McElvaney, Kenneth R. Chapman & Jonathan M. Edelman. (2017) Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency. British Journal of Clinical Pharmacology 83:11, pages 2386-2397.
Crossref
Janet Fricker. (2017) Transitioning Clinical Data into Patient Care: Recent Real-Life Experiences with Alpha 1. EMJ Respiratory, pages 32-40.
Crossref
Theodore Kelbel, Darren Morris, Deirdre Walker, Maria Paula Henao & Timothy Craig. (2017) The Allergist's Role in Detection of Severe Alpha-1 Antitrypsin Deficiency. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages 1302-1306.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez‐Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology 22:3, pages 575-601.
Crossref
Scott M. Gordon & Alan T. Remaley. (2017) High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis 259, pages 104-113.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal 49:3, pages 1700214.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M. G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agustí. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine 195:5, pages 557-582.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martínez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolás Roche, Roberto Rodríguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agustí. (2017) Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. Archivos de Bronconeumología 53:3, pages 128-149.
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos de Bronconeumología (English Edition) 53:3, pages 128-149.
Crossref
Noel G McElvaney, Jonathan Burdon, Mark Holmes, Allan Glanville, Peter A B Wark, Philip J Thompson, Paul Hernandez, Jan Chlumsky, Helmut Teschler, Joachim H Ficker, Niels Seersholm, Alan Altraja, Riitta Mäkitaro, Joanna Chorostowska-Wynimko, Marek Sanak, Paul I Stoicescu, Eeva Piitulainen, Oliver Vit, Marion Wencker, Michael A Tortorici, Michael Fries, Jonathan M Edelman & Kenneth R Chapman. (2017) Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). The Lancet Respiratory Medicine 5:1, pages 51-60.
Crossref
Ignacio Blanco. 2017. Blanco's Overview of Alpha-1 Antitrypsin Deficiency. Blanco's Overview of Alpha-1 Antitrypsin Deficiency
175
191
.
Robert Stockley. 2017. Alpha-1-antitrypsin Deficiency. Alpha-1-antitrypsin Deficiency
101
116
.
Michael Campos & Jorge Lascano. 2017. Alpha-1 Antitrypsin Deficiency. Alpha-1 Antitrypsin Deficiency
249
262
.
Kate McKeage & Katherine A. Lyseng-Williamson. (2016) Human α1-proteinase inhibitor (Respreeza®) in α1-antitrypsin deficiency emphysema: a guide to its use in the EU. Drugs & Therapy Perspectives 32:10, pages 422-427.
Crossref
Peter C Gøtzsche & Helle Krogh Johansen. (2016) Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database of Systematic Reviews 2016:9.
Crossref
Cormac McCarthy, Emer P. Reeves & Noel G. McElvaney. (2016) The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency. Annals of the American Thoracic Society 13:Supplement_4, pages S297-S304.
Crossref
Jared T. Perrin & Cassie C. Kennedy. (2016) 48-Year-Old Man With Dyspnea on Exertion. Mayo Clinic Proceedings 91:4, pages 509-513.
Crossref
Timm Greulich. 2016. Seltene Lungenerkrankungen. Seltene Lungenerkrankungen
369
383
.
Haala K. Rokadia & James K. Stoller. (2015) Surgical and Bronchoscopic Lung Volume Reduction Treatment for α-1 Antitrypsin Deficiency. Clinical Pulmonary Medicine 22:6, pages 279-285.
Crossref
C E Green, S Vayalapra, J A Hampson, D Mukherjee, R A Stockley & A M Turner. (2015) PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax 70:10, pages 939-945.
Crossref
Damian Bruce-Hickman, Catherine M. Greene & Bibek Gooptu. 2015. Controversies in COPD. Controversies in COPD
47
84
.
Daniela Giacoboni, Miriam Barrecheguren, Cristina Esquinas, Esther Rodríguez, Cristina Berastegui, Manuel López-Meseguer, Víctor Monforte, Carlos Bravo, Pietro Pirina, Marc Miravitlles & Antonio Román. (2015) Características de la población candidata a trasplante pulmonar por enfermedad pulmonar obstructiva crónica y por enfisema secundario a déficit de alfa 1 antitripsina. Archivos de Bronconeumología 51:8, pages 379-383.
Crossref
Daniela Giacoboni, Miriam Barrecheguren, Cristina Esquinas, Esther Rodríguez, Cristina Berastegui, Manuel López-Meseguer, Víctor Monforte, Carlos Bravo, Pietro Pirina, Marc Miravitlles & Antonio Román. (2015) Characteristics of Candidates for Lung Transplantation Due to Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency Emphysema. Archivos de Bronconeumología (English Edition) 51:8, pages 379-383.
Crossref
Kenneth R Chapman, Jonathan G W Burdon, Eeva Piitulainen, Robert A Sandhaus, Niels Seersholm, James M Stocks, Berend C Stoel, Liping Huang, Zhenling Yao, Jonathan M Edelman & Noel G McElvaney. (2015) Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. The Lancet 386:9991, pages 360-368.
Crossref
Francisco Casas, Ignacio Blanco, María Teresa Martínez, Ana Bustamante, Marc Miravitlles, Sergio Cadenas, José M. Hernández, Lourdes Lázaro, Esther Rodríguez, Francisco Rodríguez-Frías, María Torres & Beatriz Lara. (2015) Actualización sobre indicaciones de búsqueda activa de casos y tratamiento con alfa-1 antitripsina por vía intravenosa en pacientes con enfermedad pulmonar obstructiva crónica asociada a déficit de alfa-1 antitripsina. Archivos de Bronconeumología 51:4, pages 185-192.
Crossref
Francisco Casas, Ignacio Blanco, María Teresa Martínez, Ana Bustamante, Marc Miravitlles, Sergio Cadenas, José M. Hernández, Lourdes Lázaro, Esther Rodríguez, Francisco Rodríguez-Frías, María Torres & Beatriz Lara. (2015) Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update. Archivos de Bronconeumología (English Edition) 51:4, pages 185-192.
Crossref
Helmut Teschler. (2015)
Long-term experience in the treatment of α
1
-antitrypsin deficiency: 25 years of augmentation therapy
. European Respiratory Review 24:135, pages 46-51.
Crossref
Michael A. Campos & Jorge Lascano. (2014) α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy. Therapeutic Advances in Respiratory Disease 8:5, pages 150-161.
Crossref
F. de Serres & I. Blanco. (2014) Role of alpha-1 antitrypsin in human health and disease. Journal of Internal Medicine 276:4, pages 311-335.
Crossref
Cormac McCarthy, Radka Saldova, Mark R WormaldPauline M. Rudd, Noel G. McElvaney & Emer P. Reeves. (2014) The Role and Importance of Glycosylation of Acute Phase Proteins with Focus on Alpha-1 Antitrypsin in Acute and Chronic Inflammatory Conditions. Journal of Proteome Research 13:7, pages 3131-3143.
Crossref
Anilkumar P. Pillai, Alice M. Turner & Robert A. Stockley. (2014)
Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease Strategy to Clinically Relevant Outcomes in Individuals with α
1
-Antitrypsin Deficiency
. Annals of the American Thoracic Society 11:6, pages 859-864.
Crossref
Robert A. Stockley. (2014) Alpha1-antitrypsin Review. Clinics in Chest Medicine 35:1, pages 39-50.
Crossref
Robert A. Stockley & Alice M. Turner. (2014) α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine 20:2, pages 105-115.
Crossref
Robert A. Stockley. (2013) α 1 -Antitrypsin Deficiency. Chest 144:6, pages 1923-1929.
Crossref
F. Lebargy. (2013) Les 50 ans de la découverte du déficit en alpha-1 antitrypsine. Revue des Maladies Respiratoires Actualités 5:6, pages 607-611.
Crossref
Alice M. Turner. (2013) Alpha-1 Antitrypsin Deficiency: New Developments in Augmentation and Other Therapies. BioDrugs 27:6, pages 547-558.
Crossref
Anilkumar P. Pillai, Alice M. Turner & Robert A. Stockley. (2013) Global Initiative for Chronic Obstructive Lung Disease 2011 Symptom/Risk Assessment in α 1 -Antitrypsin Deficiency. Chest 144:4, pages 1152-1162.
Crossref
Timm Greulich, Stefania Ottaviani, Robert Bals, Philipp M. Lepper, Claus Vogelmeier, Maurizio Luisetti & Ilaria Ferrarotti. (2013) Alpha1-antitrypsin deficiency – Diagnostic testing and disease awareness in Germany and Italy. Respiratory Medicine 107:9, pages 1400-1408.
Crossref
Alice M. Turner. (2013) Fifty Years On: GWAS Confirms the Role of a Rare Variant in Lung Disease. PLoS Genetics 9:8, pages e1003768.
Crossref
Kim Hoenderdos & Alison Condliffe. (2013) The Neutrophil in Chronic Obstructive Pulmonary Disease. Too Little, Too Late or Too Much, Too Soon?. American Journal of Respiratory Cell and Molecular Biology 48:5, pages 531-539.
Crossref
Bruce C Trapnell & Maurizio Luisetti. (2013) The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases 8:1, pages 153.
Crossref
Robert A Stockley, Marc Miravitlles & Claus Vogelmeier. (2013) Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet Journal of Rare Diseases 8:1, pages 149.
Crossref
Chad K. Oh & Nestor A. Molfino. 2013. Emery and Rimoin's Principles and Practice of Medical Genetics. Emery and Rimoin's Principles and Practice of Medical Genetics
1
33
.
D.W. Cox. 2013. Brenner's Encyclopedia of Genetics. Brenner's Encyclopedia of Genetics
85
87
.
Marilyn G. Foreman, Michael Campos & Juan C. Celedón. (2012) Genes and Chronic Obstructive Pulmonary Disease. Medical Clinics of North America 96:4, pages 699-711.
Crossref
Michael Campos, Diego Shmuels & John Walsh. (2012) Detection of Alpha-1 Antitrypsin Deficiency in the US. The American Journal of Medicine 125:7, pages 623-624.
Crossref
Maureen M. J. Guichelaar & Michael R. Charlton. 2012. Medical Care of the Liver Transplant Patient. Medical Care of the Liver Transplant Patient
97
109
.
Juan Carlos Barros-Tizón, María Luisa Torres, Ignacio Blanco & María Teresa Martínez. (2012) Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Therapeutic Advances in Respiratory Disease 6:2, pages 67-78.
Crossref
David A. Bergin, Killian Hurley, Noel G. McElvaney & Emer P. Reeves. (2012) Alpha-1 Antitrypsin: A Potent Anti-Inflammatory and Potential Novel Therapeutic Agent. Archivum Immunologiae et Therapiae Experimentalis 60:2, pages 81-97.
Crossref
James K. Stoller & Loutfi S. Aboussouan. (2012)
A Review of α
1
-Antitrypsin Deficiency
. American Journal of Respiratory and Critical Care Medicine 185:3, pages 246-259.
Crossref
Moshe Zutler, Patricia J Quinlan & Paul D Blanc. (2011) Alpha-1-antitrypsin deficient man presenting with lung function decline associated with dust exposure: a case report. Journal of Medical Case Reports 5:1.
Crossref
Frank Tacke & Christian Trautwein. (2011) Controlling autophagy: A new concept for clearing liver disease. Hepatology 53:1, pages 356-358.
Crossref
R. Siekmeier. (2010) Lung deposition of inhaled Alpha-1-proteinase inhibitor (Alpha1-PI) - problems and experience of Alpha1-PI inhalation therapy in patients with hereditary Alpha1-PI deficiency and cystic fibrosis. European Journal of Medical Research 15:S2.
Crossref
James M Stocks, Mark L Brantly, Laurene Wang-Smith, Michael A Campos, Kenneth R Chapman, Friedrich Kueppers, Robert A Sandhaus, Charlie Strange & Gerard Turino. (2010) Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study. BMC Clinical Pharmacology 10:1.
Crossref
Adriano R. Tonelli & Mark L. Brantly. (2010) Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Therapeutic Advances in Respiratory Disease 4:5, pages 289-312.
Crossref
Peter C Gøtzsche & Helle Krogh Johansen. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Theodore G. Liou, Eric P. Elkin, David J. Pasta, Joan R. Jacobs, Michael W. Konstan, Wayne J. Morgan & Jeffrey S. Wagener. (2010) Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis 9:4, pages 250-256.
Crossref
. (2009)
Alpha
1
-Antitrypsin Deficiency
. New England Journal of Medicine 361:21, pages 2101-2102.
Crossref